Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BIOCRYST PHARMACEUTICALS INC (BCRX)

BioCryst Q3 revenue rises 13% to $180.3 million; GAAP net income $37.9 million

Positive Impact 4 of 5 guidance Written later

BioCryst reported third quarter 2026 total revenue of $180.3 million, up 13% from a year earlier, and GAAP net income of $37.9 million, compared with $12.9 million in the same quarter of 2025. The company raised its full year 2026 total revenue outlook to $715 million to $730 million and lowered its non-GAAP operating expense outlook to $415 million to $425 million, while keeping its ORLADEYO revenue outlook at $625 million to $645 million. The filing says part of the revenue growth reflects an initial inventory build by its new specialty pharmacy, CareMed.

Key points

  • Q3 2026 total revenue was $180.3 million, up from $159.4 million in Q3 2025; GAAP net income was $37.9 million, or $0.14 per diluted share, versus $12.9 million.
  • Full year 2026 total revenue guidance was raised to $715 million to $730 million from $690 million to $715 million, driven mainly by navenibart rights licensing and higher RAPIVAB orders.
  • ORLADEYO revenue guidance was unchanged at $625 million to $645 million; non-GAAP operating expense guidance was lowered to $415 million to $425 million from $420 million to $440 million.
  • The Birmingham site closure is expected to cost about $10 million in cash and produce annualized savings of $30 million to $35 million once fully realized.

The filing

CompanyBIOCRYST PHARMACEUTICALS INC (BCRX)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:03 AM ET
Accession number0001171843-26-007097

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.